CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.174
https://www.valueinhealthjournal.com/article/S1098-3015(23)03304-1/fulltext
Title :
CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03304-1&doi=10.1016/j.jval.2023.09.174
First page :
Section Title :
Open access? :
No
Section Order :
11182